Daniel O'Day, Gilead CEO (Andrew Harnik/AP Images)
October 27, 2022 07:32 PM EDTUpdated October 28, 07:04 AM
Pharma
FDA+

Gilead­'s $1.7B hep D drug just ran in­to a road­block at the FDA

Nicole DeFeudis

Editor

Gilead was fol­low­ing Ger­man biotech Myr and its he­pati­tis delta virus can­di­date for “quite some time” be­fore fi­nal­ly pulling the trig­ger on a $1.7 bil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

Sang­amo strikes an­oth­er brain-tar­get­ing AAV part­ner­ship, this time with Astel­las

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Ex­clu­sive: Col­or Health alums raise $10M for new start­up, us­ing AI for reg­u­la­to­ry work

A service from the Financial Times